A study published in the Current Medical Research and Opinion journal assessed the achievement of composite endpoints of glycated hemoglobin (HbA1c), body weight (BW), and systolic blood pressure (BP) targets with canagliflozin in comparison with placebo in patients with type 2 diabetes mellitus. The results demonstrated clinically significant reductions in these parameters in those who were administered canagliflozin. At week 26, greater number of patients achieved the composite endpoint of HbA1c reduction ≥ 0.5%, BW reduction ≥ 3%, and systolic BP reduction ≥ 4 mmHg with canagliflozin than with placebo. Moreover, a larger proportion of patients attained the composite endpoint of HbA1c < 7%, BW reduction ≥ 3%, and BP < 130/80 mmHg with canagliflozin in contrast to those who were given placebo. Canagliflozin displayed a favorable tolerability profile.